# US 8,278,330 B2 · Short duration depot formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,330 B2
- Document ID: US8278330B2
- Status: Granted
- Kind: B2
- Application number: 12/924,441
- Filed: 2010-09-27
- Published: 2011-02-24
- Granted: 2012-10-02
- Earliest claimed: 2002-06-25
- Assignees: Durect Corporation
- Inventors: Guohua Chen; David Priebe
- Web page: https://patentgrep.com/patent/US8278330B2

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 23/00: Anaesthetics
- A61P 23/02: Local anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

## Claims

### Claim 1

A sustained release dosage form of an anesthetic, said dosage form comprising:
a short duration gel vehicle comprising a low molecular weight bioerodible, biocompatible polymer and a water-immiscible solvent in an amount effective to plasticize the polymer and form a gel therewith; and
an anesthetic dissolved or dispersed in the gel vehicle, wherein said polymer is a lactic acid-based polymer having a weight average molecular weight from about 3,000 to about 10,000, said solvent is benzyl alcohol, and said anesthetic is bupivacaine, and further wherein the dosage form provides for a reduced initial burst of the anesthetic from the dosage form after local administration.

### Claim 2 (depends on 1)

The sustained release dosage form of claim 1, wherein the sustained release occurs in a period of less than or equal to about seven days.

### Claim 3 (depends on 2)

The sustained release dosage form of claim 2, wherein the sustained release lasts for a period of between about 24 hours to about seven days.

### Claim 4 (depends on 2)

The sustained release dosage form of claim 2, wherein the sustained release lasts for a period of about three days.

### Claim 5 (depends on 1)

The sustained release dosage form of claim 1, wherein the polymer comprises a copolymer of lactic acid and glycolic acid (PLGA).

### Claim 6 (depends on 5)

The sustained release dosage form of claim 5, wherein the copolymer has a monomer ratio of lactic acid to glycolic acid of approximately 50:50.

### Claim 7 (depends on 1)

The sustained release dosage form of claim 1, wherein the polymer has a weight average molecular weight of between about 3,000 and about 8,000.

### Claim 8 (depends on 1)

The sustained release dosage form of claim 1, wherein the dosage form comprises from about 1% to about 30% anesthetic by weight.

### Claim 9 (depends on 1)

The sustained release dosage form of claim 1, wherein the anesthetic comprises particles having an average particle size of less than about 250 μm.

### Claim 10 (depends on 1)

The sustained release dosage form of claim 1, wherein the anesthetic comprises particles of bupivacaine base.
